Finance

Lists
Why is KLRA up 3.20%?
Dive Deeper
KLRA:NASDAQ
Kailera Therapeutics Inc
$11.61
+3.20%
(+0.36) 1D
Oct 19, 12:58:34 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KLRA...
Open
$11.34
High
$11.69
Low
$11.18
Mkt. cap
1.51B
Avg. vol.
1.34M
Volume
280.86K
52-wk high
$28.23
52-wk low
$9.76
No. of employees
145
Open
$11.34
High
$11.69
Low
$11.18
Mkt. cap
1.51B
Avg. vol.
1.34M
Volume
280.86K
52-wk high
$28.23
52-wk low
$9.76
No. of employees
145
News stories
From web sources and news partners
About Kailera Therapeutics Inc
CEO-
Employees145
Founded2024
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitekailera.com
Analyst ratings
Based on 4 analysts giving stock ratings to KLRA in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for KLRA in the last 3 months.
Highest
Current $11.61
$57.00 (+390.96%)
Average
$45.00 (+287.60%)
Lowest
$30.00 (+158.40%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andy Hsieh
William Blair
Buy
Maintained
-
-
09/30/2026
Yaron Werber
TD Cowen
Buy
Maintained
$57.00
+391%
09/29/2026
Roger Song
Jefferies
Buy
Maintained
$48.00
+313.4%
08/14/2026
Hardik Parikh
J.P. Morgan
Buy
Maintained
$30.00
+158.4%
08/12/2026
Umer Raffat
Evercore ISI
Buy
Initiated
-
-
05/12/2026
Last report
Aug 12, 2026
Fiscal period
Q2 2026
-$1.09 / -$0.73
-49.39%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10.13M
19.52M
70.87M
101.06M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.33M
11.13M
13.79M
20.31M
Operating expense
20.46M
30.65M
84.66M
121.37M
Total operating expenses
20.46M
30.65M
84.66M
121.37M
Operating income
-20.46M
-30.65M
-84.66M
-121.37M
Other non operating income
800.00K
-422.00K
79.00K
72.00K
EBT including unusual items
-17.98M
-28.95M
-78.86M
-111.31M
EBT excluding unusual items
-17.98M
-28.95M
-78.86M
-111.31M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17.98M
-28.95M
-78.86M
-111.31M
Net profit margin
-
-
-
-
Earnings per share
-
-
-3.65
-1.09
Interest and investment income
1.68M
2.13M
5.72M
9.99M
Interest expense
-
-
-
-
Net interest expenses
1.68M
2.13M
5.72M
9.99M
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.40M
-30.59M
-84.56M
-121.27M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps